Defence Therapeutics Inc., a Canadian biopharmaceutical company, has announced the publication of its new international patent application for its proprietary AccumTM technology. This technology is designed to deliver CRISPR/Cas genome-editing complexes into cells, bypassing the problem of endosomal entrapment.
The patent application, published by the World Intellectual Property Organization (WIPO), demonstrates the successful delivery of various therapeutic cargoes, including polynucleotides, recombinant proteins, and nucleoprotein complexes. The application also showcases the delivery of functional CRISPR/Cas9 and guide RNA ribonucleoprotein complexes by AccumTM variants.
The effectiveness of Defence&https://adarima.org/?aHR0cHM6Ly9tY3J5cHRvLmNsdWIvY2F0ZWdvcnJ5Lz93cHNhZmVsaW5rPXRObTJ3aGdrMWJ3QXBic0NhZGZFZUZsZ2lIbmlrWTJWVlUxcEpiM04yYkV4MkszTndSV1JUS3l0M1FUMDk-8217;s AccumTM technology for delivering large and functional ribonucleoprotein complexes into the nucleus of cells represents a significant breakthrough. This discovery opens up possibilities for future collaborations in the field of genome editing and may address a roadblock in the development of genome editing-based therapies.
The published patent application also includes in vivo data showing the efficacy of Defence&https://adarima.org/?aHR0cHM6Ly9tY3J5cHRvLmNsdWIvY2F0ZWdvcnJ5Lz93cHNhZmVsaW5rPXRObTJ3aGdrMWJ3QXBic0NhZGZFZUZsZ2lIbmlrWTJWVlUxcEpiM04yYkV4MkszTndSV1JUS3l0M1FUMDk-8217;s AccumTM technology in transforming non-antigen presenting and immune quiescing cells, such as mesenchymal stem cells (MSCs), into efficient antigen presenters and immunostimulatory cells. This innovation led to the development of Defence&https://adarima.org/?aHR0cHM6Ly9tY3J5cHRvLmNsdWIvY2F0ZWdvcnJ5Lz93cHNhZmVsaW5rPXRObTJ3aGdrMWJ3QXBic0NhZGZFZUZsZ2lIbmlrWTJWVlUxcEpiM04yYkV4MkszTndSV1JUS3l0M1FUMDk-8217;s second-generation MSC-based therapeutic ARM vaccine for lymphoma, which demonstrated outstanding results in a recent pre-clinical study.
The filing and publication of this patent application mark a significant step towards commercializing and gaining approval for Defence&https://adarima.org/?aHR0cHM6Ly9tY3J5cHRvLmNsdWIvY2F0ZWdvcnJ5Lz93cHNhZmVsaW5rPXRObTJ3aGdrMWJ3QXBic0NhZGZFZUZsZ2lIbmlrWTJWVlUxcEpiM04yYkV4MkszTndSV1JUS3l0M1FUMDk-8217;s innovative therapeutic and prophylactic candidates. The company&https://adarima.org/?aHR0cHM6Ly9tY3J5cHRvLmNsdWIvY2F0ZWdvcnJ5Lz93cHNhZmVsaW5rPXRObTJ3aGdrMWJ3QXBic0NhZGZFZUZsZ2lIbmlrWTJWVlUxcEpiM04yYkV4MkszTndSV1JUS3l0M1FUMDk-8217;s rapidly-growing patent portfolio reflects its commitment to bringing innovative therapeutic technologies to market and making a lasting impact on the lives of patients.
Defence Therapeutics is a biotechnology company focused on engineering next-generation vaccines and antibody-drug conjugate (ADC) products using its proprietary platform. The company&https://adarima.org/?aHR0cHM6Ly9tY3J5cHRvLmNsdWIvY2F0ZWdvcnJ5Lz93cHNhZmVsaW5rPXRObTJ3aGdrMWJ3QXBic0NhZGZFZUZsZ2lIbmlrWTJWVlUxcEpiM04yYkV4MkszTndSV1JUS3l0M1FUMDk-8217;s platform utilizes two ground-breaking technologies, AccumTM and AccuTOX™, which enable precision delivery of vaccine antigens or ADCs to target cells and induce potent killing of cancer cells, respectively. These technologies enhance the efficacy and potency of treatments against cancer and infectious diseases.
For more information, contact Sebastien Plouffe, President, CEO, and Director of Defence Therapeutics. The company&https://adarima.org/?aHR0cHM6Ly9tY3J5cHRvLmNsdWIvY2F0ZWdvcnJ5Lz93cHNhZmVsaW5rPXRObTJ3aGdrMWJ3QXBic0NhZGZFZUZsZ2lIbmlrWTJWVlUxcEpiM04yYkV4MkszTndSV1JUS3l0M1FUMDk-8217;s contact information is provided below.
In conclusion, Defence Therapeutics Inc.&https://adarima.org/?aHR0cHM6Ly9tY3J5cHRvLmNsdWIvY2F0ZWdvcnJ5Lz93cHNhZmVsaW5rPXRObTJ3aGdrMWJ3QXBic0NhZGZFZUZsZ2lIbmlrWTJWVlUxcEpiM04yYkV4MkszTndSV1JUS3l0M1FUMDk-8217;s recent patent application publication highlights the effectiveness of its AccumTM technology for delivering CRISPR/Cas genome-editing complexes and other therapeutically relevant cargoes. This breakthrough has implications for genome editing-based therapies and opens up opportunities for future collaborations. Defence Therapeutics continues to make significant advancements in its quest to bring innovative therapeutic technologies to market and improve patient outcomes.
Disclaimer: This article contains forward-looking statements concerning the future growth and prospects of Defence Therapeutics Inc. These statements are based on the beliefs, estimates, and opinions of the company&https://adarima.org/?aHR0cHM6Ly9tY3J5cHRvLmNsdWIvY2F0ZWdvcnJ5Lz93cHNhZmVsaW5rPXRObTJ3aGdrMWJ3QXBic0NhZGZFZUZsZ2lIbmlrWTJWVlUxcEpiM04yYkV4MkszTndSV1JUS3l0M1FUMDk-8217;s management at the time of writing and are subject to various risks and uncertainties. Actual results may differ materially from those projected in the forward-looking statements. Investors are advised to exercise caution and conduct their own due diligence before making any investment decisions.
